Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Radiopharm achieves Nasdaq listing of ADS

Wednesday, November 27, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has successfully achieved a listing on Nasdaq for its American Depositary Shares (ADS). This milestone reflects the company's growth and commitment to advancing its clinical programs, including the ongoing Phase 1/2a study of BetaBart (RV-01). The company has also received positive feedback on its clinical updates across several programs.

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm achieved a Nasdaq listing for its American Depositary Shares.
  • The company is advancing its clinical programs, including BetaBart.
  • Positive clinical updates have been shared across multiple programs.

Full Press Release Details

• Announcements
• November 27, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• November 25, 2021
• Announcements
• December 2, 2022
• Announcements
• November 22, 2022
• Announcements
• March 28, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What recent milestone did Radiopharm achieve?

Radiopharm has achieved a listing on Nasdaq for its American Depositary Shares.

What is BetaBart in relation to Radiopharm?

BetaBart (RV-01) is a key product undergoing a Phase 1/2a clinical study by Radiopharm.

What type of updates has Radiopharm provided?

Radiopharm has shared positive clinical updates across multiple programs.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Nasdaq BetaBart clinical updates
Last updated: Nov 27, 2024